8
views
0
recommends
+1 Recommend
1 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: found

      Heart Rhythm in Patients with Neurofibromatosis Type 1

      research-article
      , ,
      Cardiology
      S. Karger AG
      Neurofibromatosis 1, Arrhythmias, Bradycardia, Holier monitoring

      Read this article at

      ScienceOpenPublisherPubMed
      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          Neurofibromatosis type 1 (NF1) is a common inherited disorder. Neurofibromas may be situated almost anywhere in the body, including mediastinum, myocardium and autonomic nervous system. We, therefore, tested our hypothesis that arrhythmias would be more common during a 24-hour period in patients with NF1 than in control subjects. In a follow-up study of NF1 patients in Gothenburg, 38 out of 47 NF1 patients entered a study for comparison with 41 controls. We did not find any excess of arrhythmias. There were, however, fewer cases with episodes of bradycardia among the NF1 patients (p < 0.01) than among the controls. This might be explained by vagus nerve involvement.

          Related collections

          Author and article information

          Journal
          CRD
          Cardiology
          10.1159/issn.0008-6312
          Cardiology
          S. Karger AG
          0008-6312
          1421-9751
          1996
          1996
          19 November 2008
          : 87
          : 4
          : 300-302
          Affiliations
          Department of Clinical Neuroscience, University of Gothenburg, Sweden
          Article
          177109 Cardiology 1996;87:300–302
          10.1159/000177109
          8793163
          17948e71-fa39-4269-96ae-2505bd529f14
          © 1996 S. Karger AG, Basel

          Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher. Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug. Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.

          History
          : 07 August 1995
          : 28 August 1995
          Page count
          Pages: 3
          Categories
          General Cardiology

          General medicine,Neurology,Cardiovascular Medicine,Internal medicine,Nephrology
          Holier monitoring,Neurofibromatosis 1,Arrhythmias,Bradycardia

          Comments

          Comment on this article